Clinical Trials
8 trialsNCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02358499 2020-12-22
Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children
Children's Mercy Hospital Kansas City
Phase 1 Completed
NCT02875743 2020-04-02
King's Invasive Aspergillosis Study II
King's College Hospital NHS Trust
Phase 4 Completed
NCT00936117 2019-02-27
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01200355 2018-05-07
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT00686543 2017-04-07
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00750737 2016-09-29
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01901172 2015-08-18
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed